A pharmacy label does not settle the ingredient question.

What compounding means

Preparing a medicine through a pharmacy, doctor or registered facility, instead of producing an approved finished product, is called compounding. It can address a patient need that an available approved product cannot meet.

The September 26, 2026 check confirmed that compounded medicines lack FDA approval. These medicines reach the market without an advance FDA check on how well they are made, whether they help or what harm they may cause.

The ingredient still has to qualify

A pharmacy’s ability to prepare medicines does not give it permission to use every raw ingredient. The rules checked September 26, 2026 did not allow a regular pharmacy to compound TB-500 from the raw ingredient. TB-500 was missing from the official permitted-ingredient list. It was also outside the FDA’s temporary group for ingredients awaiting a decision. For that group, the FDA says it may leave pharmacies alone if they meet the policy’s conditions.

The temporary policy describes cases in which the FDA plans no action against pharmacies. That policy does not approve medicines or make all uses lawful.

The FDA’s July 2026 review found that TB-500 was not an ingredient in an approved drug. It also had no official written quality standard for the raw ingredient. These are other ways an ingredient can qualify for regular pharmacy preparation. TB-500 met neither test, and staff proposed against adding it to the permitted list.

Get the proposed route in writing

Ask which exact rule the proposed preparation relies on. Have the service identify the preparing pharmacy in writing. Keep those questions separate: knowing the pharmacy’s name does not itself answer the ingredient question.

The withdrawn request is not a new permission. Under the ingredient rules checked September 26, 2026, taking back the request still did not allow a regular pharmacy to compound TB-500.